Æterna Zentaris Inc: International Partnerships

ROBUST AND BALANCED PIPELINE

Click on the product name to link directly to the product sheet.


Drug Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Marketed

120,000 Compounds Library	AEZS-115 Non-peptide LHRH antagonists (endocrinology and/or oncology) AEZS-120 Prostate cancer vaccine (oncology) AEZS-129, 131 and 132 Erk & PI3K inhibitors (oncology) AEZS-127 ErPC (oncology) AEZS-123 Ghrelin receptor antagonist (endocrinology)	AEZS-112 (oncology) AEZS-130 Therapeutic in tumor induced cachexia and others (endocrinology)	Perifosine Multiple cancers AEZS-108 Ovarian cancer, endometrial cancer	Perifosine Multiple myeloma and advanced metastatic colorectal cancer SolorelTM (AEZS-130) Diagnostic in adult growth hormone deficiency (endocrinology)	Cetrotide^® in vitro fertilization

Partners			Perifosine: Keryx North America Handok Korea (oncology)	Perifosine: Keryx North America Handok Korea (oncology)	Cetrotide: Merck Serono World ex-Japan Nippon Kayaku / Shionogi Japan

Oncology

Endocrine Therapy

Oncology & Endocrine Therapy

Contact

To inquire about partnering opportunities (in- or out-licensing), please contact our business development group:

Chantal Gravel
Director, Business Operations
Phone: (418) 652-8525
cgravel@aezsinc.com